

Index

- abdominal pain, in non-pregnant women
 bowel injury causing, 25–26, 125
 emergency gynaecological care for, 76, 195
 after laparoscopic sterilisation, 6
 ovarian torsion, 22–23, 73, 121, 191
- abdominal pain, in pregnancy
 appendicitis, 45–46, 152
 ectopic pregnancy diagnosis, 31, 38, 132, 143
 group B streptococcus and, 65, 181
 placenta abruptio, 46, 51, 153, 161
 proteinuria and headache with, 45, 151–52
 red degeneration of fibroid, 50, 158–59
- abortion. *See* termination of pregnancy
- Abortion Act 1967, 7–8, 15–16, 100–1, 111–12
- actinomycosis, copper coil IUD and, 10, 104
- acyclovir, 43–44, 148–50
- adenomyosis, 272, 293–94
- adhesiolysis, laparoscopic, 25–26, 125
- adnexal mass, ectopic pregnancy and, 38, 143
- adolescent patients
 amenorrhoea in, 83, 86–87, 92–93, 204–5, 208–9, 217, 268–69, 287–88
 cervical smears for, 9, 102
 contraceptive counselling for, 5–6, 9, 46–47, 97, 102, 153–54
 emergency contraception in, 79, 199
 female genital mutilation of, 95, 220
 human papilloma virus vaccine for, 16, 113, 263, 265–66, 280, 283–84
 infectious disease and pregnancy in, 46–47, 153–54
 menorrhagia in, 92, 216–17
 pregnancy in, 46–47, 153–54
 termination of pregnancy in, 77–78, 197
- adult respiratory distress syndrome, 273, 294
- advance directives, 63–64, 178, 273–74, 295
- air travel, during pregnancy, 48, 156
- airway management, 271–72, 292
- alcohol use, methotrexate use and, 39, 145
- ambiguous genitalia, neonatal, 62, 176–77
- amenorrhoea
 in adolescent patients, 83, 86–87, 92–93, 204–5, 208–9, 217, 268–69, 287–88
 with anorexia nervosa, 86, 90, 208, 213, 262, 278–79
 iliac fossa pain with, 75, 194
 lactational, 262, 278
 menopausal, 95, 220–21
 polycystic ovarian syndrome, 84–85, 206
 pregnancy diagnosis and, 31, 93–94, 132, 218
 primary, 87, 90, 209, 213
 production of, 268, 287
 secondary, 90, 95, 213, 220–21
 Turner syndrome, 92–93, 217
- amniotomy, 235, 255–56
- anaemic patients, travel during pregnancy and, 238, 260
- anaesthesia guidelines. *See also specific techniques*
 asthmatic patients, 271–72, 292
 cardiocographic trace abnormalities and, 68, 184–85
 pre-operative investigation of patients, 88, 211
- anorectal swab, 228–29, 247
- anorexia nervosa, amenorrhoea with, 86, 90, 208, 213, 262, 278–79
- anovulation, obesity and, 21, 119–20
- antenatal care
 adolescent patients, 46–47, 153–54

- antenatal care (cont.)
 answers to single best answer questions, 146–70
 antidepressant medications and, 49, 157
 appendicitis, 45–46, 152
 birth plan writing, 48, 156–57
 breech presentation, 49–50, 52, 158–59, 162–63
 chest pain, 52, 162
 chickenpox in pregnancy, 44, 56–57, 150, 168–69
 diabetes in pregnancy and, 43–44, 149
 domestic violence assessment during, 48, 156
 female genital mutilation, 47, 155
 gestational diabetes and, 53, 164
 ‘grand multip’ pregnancies, 45, 50, 152, 159–60
 headache in pregnancy and, 43, 45, 47, 148, 151–52, 155
 herpes simplex virus infection in pregnancy and, 43, 148–49
 HIV in pregnancy and, 42, 147
 hypertension in pregnancy and, 44, 50, 56, 150–51, 159, 167–68
 infectious disease in pregnancy, 44–47, 52, 56–57, 150–51, 153–54, 161–62, 168–69
 intrahepatic cholestasis of pregnancy, 48, 155–56
 low lying placenta, 46, 51, 152–53, 160–61
 maternal plasma DNA testing, 44, 54, 149–50, 165, 224, 240–41
 multiple births, 55, 166, 232, 251–52
 occupational health risks and, 44, 56–57, 150, 168–69
 placenta abruptio, 46, 153
 premature rupture of membranes, 42, 147
 pre-natal screening and diagnosis, 54, 164–65
 previous caesarean deliveries, 49–50, 54, 158, 165
 psychiatric problems in pregnancy, 44–45, 49, 53–55, 151, 157–58, 163, 165–66
 pubic symphysis pain, 43, 57, 148, 169
 red degeneration of fibroid, 50, 158–59
 repeated failure to attend, domestic abuse suspicion and, 48, 156
 routine vaccinations, 55, 167
 single best answer questions, 41–57
 skin rash, 41–42, 146
 syllabus, 41
 thromboembolism prophylaxis, 48, 156
 for thyroid patients, 57, 169–70
 vaginal bleeding and, 42, 46–47, 53, 146–47, 153–54, 163–64
 valproate intake, 55, 167
 antepartum haemorrhage, 46–47, 153–54
 antibiotics
 for caesarean section wound, 234, 255
 for *Chlamydia trachomatis*, 78–79, 198–99
 drug interactions of, 13–14, 108, 110, 264, 281–82
 group B streptococcus, 65, 181
 for hysterectomy, 277, 300
 for large loop excision of the transformation zone, 75, 193
 oral contraceptives and, 14, 110, 264, 281–82
 for pelvic inflammatory disease, 81, 202
 postpartum sepsis, 63, 178
 anticoagulants
 postmenopausal bleeding from, 74, 193
 pulmonary embolus therapy, 60, 173–74
 venous thromboembolism therapy, 61–62, 176
 anti-D immunoglobulin, 33, 52, 134–35, 162–63, 231, 236, 250–51, 258
 antidepressant medications
 menopause management, 95–96, 221–22
 in postpartum period, 62, 177
 in pregnancy, 44–45, 49, 151, 157
 anti-emetics
 for nausea and vomiting of pregnancy, 30–31, 131–32
 for pre-emptive treatment of hyperemesis, 34, 136–37
 anti-epileptic drugs, 55, 167
 antihypertensives, in pregnancy, 39, 144
 antiphospholipid syndrome, 38, 142, 274–75, 296
 antiretroviral therapy, 42, 59, 147, 172–73
 anxiety, menopause with, 95–96, 221–22
 Apgar scoring, 226, 243–44
 appendicitis
 differential diagnosis, 20–23, 31, 118–19, 121, 132
 foetor oris and, 45–46, 152

- Asherman syndrome, amenorrhoea with, 90, 213
- aspiration pneumonitis, 68, 184–85
- aspirin
 antiphospholipid syndrome management, 38, 142
 pre-eclampsia prevention and, 56, 167–68, 232–33, 252–53
- assisted conception treatment. *See also* in vitro fertilisation
 complications of, 20–23, 29, 34, 118–22, 130, 136
 rubella vaccination before, 23, 122
- assisted vaginal delivery
 indications for, 69, 185
 risks associated with, 237, 259
 strategies to prevent, 48, 156–57
- asthmatic patients, anaesthesia
 complications in, 271–72, 292
- atosiban, 237, 259–60
- atrophic vaginitis, 94, 219
- autoimmune disease, lichen sclerosus with, 94, 219–20
- avascular necrosis, 80, 200
- azoospermia, 28, 129
- B vitamins, 32, 134
- bacterial vaginosis, 45, 151, 227–28, 245–46, 270, 290
- Bartholin's abscess, 81–82, 202–3
- benzylpenicillin, group B streptococcus, 65, 181
- beta-hCG
 blood test, 80–81, 201
 complete hydatidiform mole follow-up, 35, 138
 ectopic pregnancy diagnosis, 38, 142–43
 partial hydatidiform mole levels of, 30, 131
 urinary, 75, 194
- beta-hemolytic streptococcus. *See* group B streptococcus
- bipolar disorder
 pregnancy in, 49, 157–58, 230, 249
 puerperal psychosis risk in, 63, 177–78
- birth plan, 48, 156–57
- birthing pools, 234, 254–55
- bisphosphonate, 96, 222
- bladder cancer, cystoscopy for diagnosis of, 85, 207
- bladder diary, 96, 222
- bladder disorders
 diagnosis and management, 271, 291
 laparoscopic sterilisation, 6, 97–98
 unstable bladder, 92, 215–16
- bladder drill, 92, 215–16
- bladder pain syndrome, 96, 222
- bladder pressure studies, 90, 213, 265, 283
- blood pressure. *See also* pre-eclampsia hypertension in pregnancy and, 39, 144
 maternal obesity and, 44, 150–51, 231, 251
- blood transfusion. *See* transfusion
- bone-sparing drug treatment, 96, 222
- bowel damage, laparoscopy and risk of, 6, 21, 25–26, 97–98, 119, 125
- BRCA1 gene, 266, 284
- BRCA2 gene, 266, 284
- breakthrough bleeding, 15, 110–11
- breast abscess, 236, 257
- breast cancer, progesterone-only pill and, 276, 298
- breast development, 93, 218
- breastfeeding
 for diabetic mothers, 226, 244
 HIV infection as contraindication to, 59, 172–73
 hypertension management during, 71, 189
 lactational amenorrhoea and, 262, 278
 nipple soreness, 58, 171, 238, 261
 suppression of lactation after stillbirth, 71, 188
- breech presentation
 caesarean section for, 54, 165, 229–30, 248
 cord prolapse and, 50, 159
 external cephalic version for, 49, 52, 158, 162–63
 postpartum counselling concerning, 61, 175–76
- CA125 blood test
 ovarian cancer and, 81, 201–2, 270, 275, 290–91, 296–97
 ovarian cysts, 77, 93, 196–97, 217–18
 risk of malignancy index and, 90, 213–14
 trans-vaginal ultrasound and, 81, 201–2
- cabergoline, 71, 188
- caesarean section. *See also* vaginal birth after caesarean
 bladder complications and, 6, 97–98

- caesarean section (cont.)
 for breech presentation, 54, 165,
 229–30, 248
 consent for, 69–70, 186–87
 cord prolapse and, 235, 256
 decision-to-delivery intervals for, 223,
 239
 HIV-positive mother, neonatal care
 following, 59, 172–73
 indications for, 223, 239
 laparoscopy complications following,
 21, 119
 low lying placenta and, 36–37, 140,
 237, 260
 ovarian cystectomy during, 70, 187
 postpartum management, 67, 183
 pulmonary embolus following, 60,
 173–74
 venous thromboembolism following,
 61–62, 176
 wound dehiscence, 65, 180
 wound infection, 234, 255
- cancer patients. *See also specific cancers*
 assessment of possible, 85–86, 207
 haematometria following cervical
 cancer therapy, 86, 208
- Candida albicans* infection
 therapy for, 9–10, 13, 103, 108
 vaginal discharge with, 18, 115, 270,
 290
- capacity to consent, 68, 185
- cardiac arrest, 59, 171
- cardiac disease
 assisted vaginal delivery with,
 69, 185
 pregnancy contraindications of, 7–8,
 100–1
- cardiac ischaemia, 52, 162
- cardiotocographic trace
 anaesthesia guidelines and
 abnormalities in, 68, 184–85
 vaginal bleeding and, 42, 146–47
- catheterisation, urinary retention, 65–66,
 181, 230, 248–49
- ceftriaxone, 81, 202
- cell savers, intra-operative use of, 236,
 258
- cellulitis, caesarean section wound, 234,
 255
- cerebral vein thrombosis, 61, 174–75
- Cervarix®, 265–66, 283–84
- cervical biopsy, 75, 193–94
- cervical bleeding
 cervical lesions, 75, 193–94
- large loop excision of the
 transformation zone, 75, 193
- cervical cancer
 haematometria following
 radiotherapy for, 86, 208
 human papilloma virus vaccine, 16,
 113, 263, 265–66, 280, 283–84
 screening for, 75, 193–94
- cervical dilation, 231, 250
- cervical screening
 for adolescent patients, 9, 102
 asymptomatic polyps, 92, 216
 cervical lesions and, 75, 193–94
 after gender reassignment, 13, 108
 in HIV infection, 9, 102
 human papilloma virus testing and,
 17, 114
 pelvic infection, 10, 104
 pelvic mass and, 265, 282–83
 timing for, 269, 289
- chest compressions, for maternal cardiac
 arrest, 59, 171
- chest pain, in pregnancy, 52, 162
- chickenpox in pregnancy, 44, 56–57, 150,
 168–69, 223, 225, 228, 239–42, 246
- Chlamydia trachomatis*
 in adolescent patients, 46–47, 153–54
 antibiotic prophylaxis for, 78–79,
 198–99
 endocervical swab, 21, 23, 93, 119,
 121–22, 217, 269, 288–89
 inter-menstrual bleeding with, 93, 217,
 264, 280–81
 miscarriage and screening for, 35,
 137–38
 nucleic acid amplification test for, 80,
 200
 postcoital bleeding and, 93, 217, 264,
 280–81
- chocolate ovarian cysts, treatment of, 26,
 126
- cholestasis. *See* intrahepatic cholestasis
 of pregnancy
- chorionic villus sampling, limb
 reduction defects and, 232, 252
- clear fluids, 82–83, 204
- clip sterilisation, 16, 112
- clobetasol cream, 272, 292–93
- clomifene citrate, 26, 126
- cocaine use, maternal, 57, 170
- co-cyprindiol, 268, 286–87
- colposcopy
 cervical biopsy and, 75, 193–94
 HIV infection guidelines for, 9, 102

- combined oral contraceptive (COC)
 for adolescent patients, 5–6, 97
 age contraindications to, 14, 17, 109, 113
 antibiotic use and, 14, 110
 breakthrough bleeding and, 15, 110–11
 for dysmenorrhoea, 91, 214–15
 during early pregnancy, 13–14, 109
 estrogen component of, 7, 99
 health risks of, 9, 14, 17, 102–3, 109–10, 113
 ovarian cancer protection and, 12–13, 82, 107–8, 203
 for premature ovarian insufficiency, 276, 299
 compression stockings, 48, 50–51, 156, 160
 concealed placental abruption, 51, 161
 conception, chance of, 28, 129, 274, 295–96
 confidentiality
 during labour and delivery, 62–63, 177
 sexually transmitted infection and, 276, 298–99
 violations of, 224, 240
 congenital abnormality, sodium valproate risk for, 55, 167
 congenital adrenal hyperplasia, neonatal, 62, 176–77
 congenital heart malformation, Turner syndrome, 86–87, 209
 consent, for caesarean section, 69–70, 186–87
 consent issues
 adolescent termination of pregnancy, 77–78, 197
 contraceptive counselling, 274, 296
 illiterate patients and, 69, 78, 186, 197–98
 Jehovah's Witness patients, 77, 196, 273–74, 295
 during labour and delivery, 68, 185
 non-English-speaking patients, 230, 249, 270–71, 291
 for research project participation, 69, 185–86
 sexually transmitted infection and, 276, 298–99
 constipation, 271, 291
 contact dermatitis, vulval, 94, 218–19
 contraceptive counselling. *See also specific contraceptives*
 for adolescent patients, 5–6, 9, 46–47, 97, 102, 153–54
 antibiotic interactions with
 contraceptives, 14, 110, 264, 281–82
 consent issues in, 274, 296
 drug abuse and, 11, 105
 for emergency contraception and HIV exposure, 10, 103–4
 endometrial ablation patients, 89, 212
 for epileptic patients, 12, 107
 erratic contraceptive use, 10, 16, 104, 112
 fertility after contraceptive discontinuation, 27–28, 128
 health risks of oral contraceptives, 9, 14, 17, 102–3, 109–10, 113
 high altitude trekking and, 275, 297–98
 hydatidiform mole and, 34–35, 137
 lactational amenorrhoea, 262, 278
 for learning disabled patients, 11, 106
 menopause and, 6–7, 90–91, 98–100, 214
 non-hormonal alternatives, 12, 107
 for older women, 6, 12, 14, 98–99, 106–7, 109
 polycystic ovarian syndrome, 18–19, 115–16, 268, 286–87
 in postpartum period, 12, 17, 107, 113
 quick starting of contraception, 13–14, 109
 timing of contraceptive methods, 11, 16, 105, 112
 for travel, 11–12, 106
 copper coil IUD
 actinomycosis with, 10, 104
 complications, 75, 194, 271, 291–92
 miscarriage and, 262–63, 279
 for non-hormonal contraception, 12, 107
 pelvic infection and, 10, 104
 pregnancy with, 6, 31, 98, 132
 cord prolapse
 management of, 228, 235, 246–47, 256
 prevention of, 42, 147
 risk factors for, 50, 159
 Coronavirus (Covid19) infection, 232, 251
 cross-matched blood availability
 myomectomy, 272, 293
 red cell antibodies and, 51, 160
 CT urogram, 80, 201
 Curriculum module 1
 answers to single best answer questions, 97–117

- Curriculum module 1 (cont.)
 single best answer questions, 5–19
 syllabus, 5
- Curriculum module 2
 answers to single best answer
 questions, 118–30
 single best answer questions, 20–29
 syllabus, 20
- Curriculum module 3
 answers to single best answer
 questions, 131–45
 single best answer questions, 30–40
 syllabus, 30
- Curriculum module 4
 answers to single best answer
 questions, 146–70
 single best answer questions, 41–57
 syllabus, 41
- Curriculum module 5
 answers to single best answer
 questions, 171–90
 single best answer questions, 58–72
 syllabus, 58
- Curriculum module 6
 answers to single best answer
 questions, 191–205
 single best answer questions, 73–83
 syllabus, 73
- Curriculum module 7
 answers to single best answer
 questions, 206–22
 single best answer questions, 84–96
 syllabus, 84
- cyclizine, 30–31, 34, 131–32, 136–37
- cystic teratoma, 74, 192
- cystoscopy, 85, 207, 269, 288
- The Daisy Network, 276, 299
- dating scans
 in adolescent patients, 46–47, 153–54
 missed miscarriage on, 33, 135
- deep venous thrombosis (DVT), forceps
 delivery and risk of, 64, 179
- dehydration, after gynaecological
 surgery, 88, 210
- dental care, in pregnancy, 36, 139
- depot medroxyprogesterone acetate
 (Depo Provera®)
 breakthrough bleeding with, 15,
 110–11
 erratic scheduling for, 10, 16, 104, 112
 guidelines for use of, 274, 295
 return of normal fertility after, 27–28,
 128
- timing of, 16, 112
- depression
 in postpartum period, 53–55, 62, 163,
 165–66, 177
 pregnancy and, 44–45, 49, 151, 157,
 230, 249
 in sexually abused patients, 8, 101
- dermoid cyst, 74, 192
- desogestrel, 268, 287
- detrusor instability
 bladder drill for, 92, 215–16
 bladder pressure study for, 265, 283
 multiple sclerosis and, 270, 289–90
- diabetes. *See also* gestational diabetes
 breastfeeding for mothers with, 226,
 244
 endometrial cancer and, 74, 91,
 191–92, 215, 267, 285
 ‘Enhanced Recovery Pathway,’ 82–83,
 204
 gestational, 53, 164
 maternal, neonatal management, 60,
 174
 menstrual bleeding in patients with,
 91, 215
 postpartum insulin dosage for
 mothers with, 62, 176
 pregnancy and, 43–44, 149
- diarrhoea, ectopic pregnancy and, 20–21,
 118–19, 263, 279–80
- diet, foods to avoid in pregnancy, 37,
 141
- dilation of cervix, for haematometria
 following cervical cancer therapy,
 86, 208
- direct maternal death, 64, 179
- disseminated intra vascular coagulation,
 epidural anaesthesia and, 69, 186
- domestic violence, 48, 156, 235, 256–57
- donor, egg, 27–28, 127–28
- double-dose desogestrel, 268, 287
- Down syndrome, pre-natal screening
 and diagnosis, 54, 164–65, 224,
 240–41
- drosperinone, 14, 109–10
- drug abuse
 contraception and, 11, 105
 maternal cocaine use, 57, 170
- due date calculations, 31, 132
- duloxetine, 273, 294–95
- duplex kidney, ureteric injury risk and,
 87–88, 210
- dye laparoscopy, 20, 22, 118, 120–21, 267,
 286

- pre-operative investigations, 21, 23, 119, 121–22
- dyschezia, pelvic pain with, 89, 212
- dysmenorrhoea
 - adenomyosis and, 272, 293–94
 - diagnosis of, 87–89, 209, 211
 - haematometria following cervical cancer therapy, 86, 208
 - management of, 266, 284
 - mefenamic acid for, 269–70, 289
 - treatment for, 91, 214–15
- dyspareunia
 - atrophic vaginitis, 94, 219
 - lichen planus, 95, 221
 - in older patients, 264–65, 282
 - in sexually abused patients, 8, 101
 - urinary frequency with, 85, 207
- early pregnancy. *See also* ectopic pregnancy; miscarriage
 - answers to single best answer questions, 131–45
 - molar, 30, 32–36, 131, 134, 137–39
 - nausea and vomiting in, 30–34, 36, 40, 131–32, 134, 136–37, 139, 145
 - pain in, 31, 35–36, 132, 138–39
 - single best answer questions, 30–40
 - syllabus, 30
 - ultrasound scan, 266, 284–85
 - vaginal bleeding in, 30, 38, 131, 143
- Ebola infection, pregnancy and, 52, 161–62
- ectopic pregnancy
 - diagnosis of, 31, 38, 132, 142–43
 - iliac fossa pain and, 36, 75, 140, 194
 - in vitro fertilisation and, 20–21, 118–19, 263, 279–80
 - intra-uterine pregnancy with, 34, 136
 - management of, 35–36, 74, 138–39, 192
 - methotrexate management of, 35–36, 39, 138–39, 145
 - recurrence risk of, 34, 136
 - sterilisation and risk of, 7, 99
- Edinburgh scale for postnatal depression, 54–55, 165–66
- egg donation, 27–28, 127–28
- electrolyte assessment, 75–76, 194
- emergency contraception
 - adolescent patients, 79, 199
 - HIV exposure and, 10, 103–4
 - options for, 10, 103–4, 263–64, 280
 - postcoital methods, 263–64, 280
 - rape victims, 14–15, 110
- emergency gynaecological care
 - answers to single best answer questions, 191–205
 - ectopic pregnancy diagnosis, 31, 132
 - heterotopic pregnancy, 34, 136
 - labour and delivery complications, 229–30, 248
 - miscarriage management, 35, 137–38
 - research project participation and, 69, 185–86
 - single best answer questions, 73–83
 - syllabus, 73
 - warning signs for, 76, 195
- enalapril, 71, 189
- endocervical chlamydia swab, 21, 23, 93, 119, 121–22, 217, 269, 288–89
- endometrial ablation, pre-operative investigation, 89, 212
- endometrial biopsy, 74, 191–92, 267, 285
- endometrial cancer
 - diabetes and obesity and risk of, 74, 91, 191–92, 215, 267, 285
 - endometrial hyperplasia and, 76, 194–95
 - ‘Enhanced Recovery Pathway,’ 82–83, 204
 - Jehovah’s Witness patients, 77, 196
 - polycystic ovarian syndrome and, 276–77, 299–300
 - postmenopausal bleeding and, 82, 203
- endometrial hyperplasia, 18–19, 76, 79, 84–85, 115–16, 194–95, 199, 206
- endometriosis
 - chocolate ovarian cysts with, 26, 126
 - pelvic pain and, 89, 212, 263, 279
 - ‘Enhanced Recovery Pathway,’ 82–83, 88, 204, 210
- enoxaparin, 61–62, 176
- enzyme immunoassay (EIA), 80, 200
- epididymal blockage, surgical correction of, 29, 130
- epidural anaesthesia
 - guidelines for, 68, 184–85
 - intrauterine fetal death and, 69, 186
 - in obese patients, 67, 183
- epileptic patients
 - contraception in, 12, 107
 - pregnancy management in, 55, 167
- episiotomy procedures, wound infection after, 67, 183
- ergometrine, postpartum haemorrhage management, 235, 256
- erythromycin, 13, 108

- estradiol pessaries, dyspareunia in older patients, 264–65, 282
 estradiol valerate, 7, 99
 estriol, 7, 99
 estriol cream, for labial adhesions, 85, 206–7
 estrogen
 endometrial hyperplasia and, 79, 199
 in oral contraceptives, 7, 99
 estrogen preparations, for atrophic vaginitis, 94, 219
 ethical issues, confidentiality, 62–63, 177, 224, 240
 ethinylestradiol, 7, 99
 etonogestrel implant (Nexplanon®)
 for adolescent patients, 5–6, 97
 for learning disabled patients, 11, 106
 timing of, 11, 105
 for travel, 11–12, 106
 expectant management, of miscarriage, 39, 144
 external cephalic version (ECV), 49, 52, 61, 158, 162–63, 175–76
 extrapyramidal disorders, 271, 292
- facial hirsutism, 19, 116, 268, 286–87
 Faculty of Sexual and Reproductive Health (FSRH), 274, 295
 fallopian tube removal, 266, 284
 female genital mutilation (FGM), 47, 95, 155, 220, 277, 300
 fertility, after contraceptive discontinuation, 27–28, 128
 fertility rate, age-related reduction in, 27, 127
 fertility regulation. *See also* contraceptive counselling; termination of pregnancy
 answers to single best answer questions, 97–117
 single best answer questions, 5–19
 syllabus, 5
 fertility treatments. *See* infertility
- fetal blood sampling
 anaesthesia guidelines, 68, 184–85
 fetal assessment with, 223, 239–40
 maternal positioning for, 236–37, 258–59
 fetal death, intrauterine, 69, 186
 fetal growth, assessment of, 46–47, 153–54
 fetal heart rate, 71, 188–89. *See also* cardiotocographic trace
- fetal movements, assessment of, 71, 188–89
 fetomaternal haemorrhage (FMH), 52, 162–63
 fibroids. *See* uterine fibroids
 flu vaccination, 55, 167, 233, 253
 Fluconazole, 9–10, 13, 103, 108
 foetor oris, 45–46, 152
 follicle stimulating hormone (FSH) levels
 menopausal symptoms, 95, 220–21
 ovarian failure, 93–94, 218
 foods, contraindicated in pregnancy, 37, 141
 forceps delivery
 deep venous thrombosis risk and, 64, 179
 rising spinal block and, 67, 183
 third degree tear with, 64, 178–79
 fragility fracture, 96, 222
 Fraser competency, in adolescent patients, 5–6, 9, 77–79, 97, 102, 197, 199
 free-fetal DNA testing, 44, 54, 149–50, 165, 224, 240–41
 full blood count (FBC), 273, 294
 fused labia, 85, 206–7
- Gardasil®, 265–66, 283–84
 gender reassignment, 268, 287
 cervical screening after, 13, 108
 general anaesthesia, contraindications for, 68, 184–85
 genital herpes. *See* herpes simplex virus
 genital warts, 265–66, 269, 283–84, 289
 human papilloma virus vaccine, 16, 113
 topical treatment, 19, 117
 German measles, pregnancy and exposure to, 227, 230–31, 244, 250
 gestational diabetes, antenatal care and, 53, 164
 gestational sac, iliac fossa pain and, 36, 140
 glibenclamide, 226, 244
 glucose tolerance test, 43–44, 53, 149, 164
 gonadal dysgenesis, 268–69, 287–88
 ‘grand multip’ pregnancies
 home delivery contraindicated for, 50, 159–60
 postpartum haemorrhage risk in, 45, 50, 152, 159–60, 237, 260
 granulation tissue, 78, 197
 gravidity, 32, 133–34

- 'group and save' request
 - haemorrhage management, 51, 68, 160, 184, 227, 245
 - myomectomy, 272, 293
- group B streptococcus
 - abdominal pain with, 65, 181
 - carrier status testing for, 228–29, 247
 - intra-partum antibiotics for, 65, 181
 - labour management with, 65, 181
 - meningitis in neonate and, 61, 175
 - pre-labour membrane rupture and, 233, 254
- growth scans, 46–47, 153–54
 - in adolescent patients, 46–47, 153–54
- gynaecological care
 - answers to single best answer questions, 206–22
 - cancer investigations, 85–86, 207
 - single best answer questions, 84–96
 - syllabus, 84
- gynaecological surgery. *See also specific surgeries*
 - 'Enhanced Recovery Pathway,' 82–83, 88, 204, 210
 - pre-operative investigations, 77, 88–89, 196–97, 211–12
- haematocolpos, 83, 204–5
- haematoma, paravaginal, 59, 172
- haematometria, 86, 208
- haemoglobin, placenta praevia and, 227, 245
- haemorrhage. *See also postpartum haemorrhage; vaginal bleeding*
 - with low lying placenta, 234, 255
 - myomectomy, 272–73, 293–94
 - placental abruption and, 236, 257–58
- hCG. *See beta-hCG*
- headache
 - as postpartum complication, 61, 174–75
 - in pregnancy, 43, 45, 47, 148, 151–52, 155
- heart disease. *See cardiac disease*
- heart rate, fetal, 71, 188–89. *See also* cardiotocographic trace
- heparin
 - antiphospholipid syndrome management, 38, 142
 - postmenopausal bleeding and, 74, 193
 - thromboembolism prophylaxis, 48, 156, 229, 247–48
- herpes simplex virus (HSV)
 - diagnosis of, 17, 113
 - in pregnancy, 43, 148–49
- heterotopic pregnancy, 34, 136
- high altitude trekking, 275, 297–98
- high vaginal swab, 45, 151
- hirsutism, polycystic ovarian syndrome, 19, 116, 268, 286–87
- histamine H1 receptor agonists, 30–31, 131–32
- HIV infection
 - as breastfeeding contraindication, 59, 172–73
 - cervical screening in, 9, 102
 - emergency contraception and exposure to, 10, 103–4
 - labour and delivery in patients with, 42, 147
 - neonatal care and prevention of, 42, 59, 147, 172–73
 - in pregnancy, 42, 59, 147, 172–73, 227–28, 245–46
 - pregnancy attempts with male partners positive for, 22, 121
- home births
 - contraindications, 50, 159–60
 - labour and delivery complications, 51, 161, 228, 246–47
 - postpartum complications, 62, 176–77
 - risk assessment for, 46, 153
- hormone replacement therapy (HRT)
 - estrogen component of, 7, 99
 - indications for and risks with, 266, 284
 - intrauterine system insertion and, 7, 99–100
 - for menopausal symptoms, 90–91, 214, 266, 284
 - ovarian cancer risk and, 91, 215
 - for premature ovarian insufficiency, 276, 299
 - pulmonary embolus and, 277, 300–1
 - Turner syndrome, 86–87, 209
- hospital obstetric units
 - 'maternity dashboard' in, 225, 242
 - task prioritization in, 63, 74, 178, 192
- HSA1 form, 15–16, 111–12
- human papilloma virus (HPV)
 - testing, 17, 114
 - vaccination, 16–17, 113–14, 263, 265–66, 280, 283–84
- hydatidiform mole
 - complete, 32–35, 134, 137–38
 - management of, 35–36, 138–39
 - partial, 30, 131

- hydatidiform mole (cont.)
 snowstorm appearance on ultrasound
 and, 36, 139, 268, 287
- hyperemesis
 dental complications, 36, 139
 management of, 36, 139, 224, 240, 271,
 292
 pre-emptive treatment of, 34, 136–37
 snowstorm appearance on ultrasound
 in, 36, 139
 thromboembolism risk, 40, 145
 urinary tract infection and, 76, 195
 Wernicke's encephalopathy with, 32,
 134
- hypertension. *See also* pre-eclampsia
 induction of labour for, 50, 159
 management during breastfeeding, 71,
 189
 management in pregnancy, 39, 144,
 223, 239–40
 management of, 56, 167–68
 obesity in pregnancy and, 44, 150–51,
 231, 251
 placental insufficiency and, 44, 150–51,
 231, 251
 pre-operative evaluation of
 thromboprophylaxis risk and, 89,
 211–12
- hypoglycaemia, neonatal, 60, 174
- hysterectomy
 antibiotic prophylaxis for, 277, 300
 complications, 75–78, 80, 194, 196–97,
 201
 consent for, 78, 197–98
 'Enhanced Recovery Pathway,' 82–83,
 88, 204, 210
 for menorrhagia, 273–74, 295
 oophorectomy combined with, 77, 91,
 196–97, 215, 267, 286
 pre-operative investigations, 88, 211
 ureteric injury risk of, 80, 87–88, 201,
 210
 vaginal, 89–90, 212–13
 wound dehiscence after, 88, 210–11
- hysteroscopy
 endometrial cancer, 74, 191–92
 for postmenopausal bleeding, 76,
 194–95
- iliac fossa pain
 ectopic pregnancy and, 36, 75, 140, 194
 ovarian cysts and, 275, 296–97
- illiterate patients, consent from, 69, 78,
 186, 197–98
- imiquimod cream, 19, 117
- immunisation. *See* vaccination
- implant contraceptives
 for adolescent patients, 5–6, 97
 timing of, 11, 105
 for travel, 11–12, 106
- in vitro fertilisation (IVF)
 complications of, 20–23, 29, 34, 118–22,
 130, 136
 ectopic pregnancy and, 263, 279–80
 pre-implantation genetic diagnosis
 with, 25, 124
 for unexplained infertility, 26, 125–26
- incomplete miscarriage, 39, 143–44
- induction of labour
 for hypertension, 50, 159
 maternal choice in, 70–71, 187–88
 vaginal birth after caesarean, 67–68,
 184
- infectious disease. *See also specific
 infections*
 copper coil IUD and pelvic infection,
 10, 104
 labour and delivery and, 65, 181
 neonatal, 60–61, 65, 174–75, 181
 oral contraceptives and, 15, 110–11
 in pregnancy, 44–47, 52, 56–57,
 150–51, 153–54, 161–62, 168–69, 223,
 225, 227–28, 230–31, 233, 239–42,
 244, 246, 250, 253
- infertility. *See also* in vitro fertilisation
 age-related, 27, 127
 answers to single best answer
 questions, 118–30
 chocolate ovarian cysts in, 26, 126
 drugs contributing to, 25, 124
 dye laparoscopy for assessment of, 20,
 22–23, 118, 120–22, 267, 286
 Klinefelter's syndrome with, 24–25,
 124
 NICE guidelines on referral for
 investigation of, 24, 123
 obesity in, 21, 119–20
 ovulation investigations for, 23–24,
 28–29, 122–23, 129–30
 semen analysis for, 24, 26–28, 123–24,
 126–27, 129
 single best answer questions, 20–29
 surgical management of male factor,
 29, 130
 syllabus, 20
 unexplained, 25–26, 124–26
- influenza, vaccination, 55, 167, 233, 253
- Information Governance Lead, 224, 240

- injectable contraception. *See* Depot medroxyprogesterone acetate
- insulin, postpartum dosage of, 62, 176
- inter-menstrual bleeding, *Chlamydia trachomatis*, 93, 217, 264, 280–81
- intrahepatic cholestasis of pregnancy
 antenatal care, 48, 155–56
 postpartum care, 66, 181–82
- intra-partum antibiotics, group B streptococcus, 65, 181
- intrauterine contraceptive system (IUCD)
 complications, 10, 15, 75, 104, 111, 194
 hormone avoidance and, 12, 107
 for menopausal symptoms and contraception, 90–91, 214
 for menorrhagia and contraception, 7, 99–100
 for older women, 7, 99–100
 pregnancy involving, 6, 31, 98, 132
- intrauterine fetal death, 69, 186
- intrauterine growth assessment, 46–47, 153–54
 in adolescent patients, 46–47, 153–54
- intra-uterine pregnancy, ectopic pregnancy with, 34, 136
- intravenous cannulation, indications for, in labour and delivery, 68, 184
- iron infusion, 273–74, 295
- jaundice, neonatal, 232, 252
- Jehovah's Witness patients
 consent issues with, 77, 196, 273–74, 295
 miscarriage expectant management for, 39, 144
 postpartum haemorrhage in, 63–64, 178
- karyotype
 Klinefelter's syndrome, 24–25, 124
 mosaic, 275–76, 298
 Turner syndrome, 92–93, 217
- kidney, duplex, 87–88, 210
- Kleihauer testing, 46, 52, 153, 162–63, 231, 250–51
- Klinefelter's syndrome, 24–25, 124
- labetalol, 39, 144
- labial adhesions, 85, 206–7
- labour and delivery
 breech presentation and, 49–50, 52, 158–59, 162–63
- complications during, 50–51, 67, 159–61, 183, 228, 246–47
- confidentiality issues during, 62–63, 177
- consent issues during, 68–70, 185–87
- cord prolapse prevention and management, 42, 147, 228, 235, 246–47, 256
- emergency management of, 229–30, 248
- for herpes simplex virus patients, 43, 148–49
- for HIV patients, 42, 147
- indications for assisted, 69, 185
- induction of, 50, 67–68, 70–71, 159, 184, 187–88
- infectious disease and, 65, 181
- intrauterine fetal death and, 69, 186
- intravenous cannulation, indications for, 68, 184
- multiparous patients, 55, 166
- ovarian cystectomy during, 70, 187
- partner support during, 48, 156–57
- placenta retention and delivery complications, 74, 192
- lactate levels, sepsis and, 38, 142
- lactation. *See* breastfeeding
- lactational amenorrhoea (LAM), 262, 278
- lactational breast abscess, 236, 257
- laparoscopic techniques
 adhesiolysis, 25–26, 125
 bowel damage risk from, 6, 21, 25–26, 97–98, 119, 125
 dye laparoscopy, 20–23, 118–22, 267, 286
 endometriosis, 263, 279
 sterilisation using, 6, 97–98, 264, 273, 281, 294
- large loop excision of the transformation zone (LLETZ), 75, 193
- latex allergies, 275, 297
- learning disabled patients, contraceptive options with, 11, 106
- levonorgestrel contraceptive. *See also* Mirena® IUS
 emergency contraception with, 14–15, 110
 for menorrhagia and contraception, 264, 266–67, 281–82, 285
 polycystic ovarian syndrome and, 18–19, 115–16
- lichen planus, 95, 221
- lichen sclerosus, 87, 94, 209–10, 219–20, 272, 292–93

- lichen sclerosus et atrophicus (LSA), 82, 203–4
- limb reduction defects, 232, 252
- limb swelling, in pregnancy, 50–51, 160
- listeria, 37, 141
- lithium, 49, 157–58
- liver function tests, 66, 181–82
- LMP, due date calculation using, 31, 132
- lochia, 66, 182–83
- Lovesett's manoeuvre, shoulder dystocia, 237, 259
- low birth weight infant
 maternal cocaine use and, 57, 170
 periodontitis and risk of, 36, 139
- low lying placenta
 antenatal assessment of, 46, 51, 152–53, 160–61
 caesarean section risk and, 36–37, 140, 237, 260
 haemorrhage risk with, 234, 255
- low molecular weight heparin, 48, 156, 229, 247–48
- low vaginal swab, 228–29, 247
- luteinising hormone (LH) levels, ovarian failure, 93–94, 218
- macrosomia, 59, 172
- marsupialisation, of Bartholin's abscess, 81–82, 202–3
- Marvelon® oral contraceptive, 19, 116
- maternal morbidity and mortality, 52–53, 163
 blood pressure levels and, 44, 150–51, 231, 251
 cardiac complications in, 7–8, 100–1
 denominators for, 229, 247
 direct maternal death, 64, 179
 epilepsy and, 55, 167
 morbid obesity and, 21, 119–20
 suicide as cause of, 54–55, 165–66, 230, 249
 thromboembolism and, 60, 173–74
- maternal plasma DNA, non-invasive testing using, 44, 54, 149–50, 165, 224, 240–41
- 'maternity dashboard' in hospital obstetric units, 225, 242
- Mauriceau-Smellie-Veit manoeuvre, shoulder dystocia, 237, 259
- Mayer-Rokitansky-Kuster-Hauser syndrome, 268–69, 287–88
- McRobert's manoeuvre, shoulder dystocia, 237, 259
- measles, pregnancy and, 227, 244
- meconium, intrahepatic cholestasis of pregnancy and, 48, 155–56
- medical abortion, 18, 115
- medroxyprogesterone acetate. *See* Depot medroxyprogesterone acetate
- mefenamic acid, 269–70, 289
- membrane rupture
 group B streptococcus and, 233, 254
 pre-labour premature rupture of membranes, 71–72, 184–89, 225, 242
 premature, 42, 147
- menarche, 93, 218
- Mendelssohn's syndrome, 68, 184–85
- meningitis, neonatal, 61, 175
- menopause
 assessment of, 95, 220–21
 contraceptive counselling and, 6–7, 90–91, 98–100, 214
 hormone replacement therapy and, 90–91, 214, 266, 284
 malignancy symptoms and, 85, 207
 management of, 90–91, 95–96, 214, 221–22
 risk of malignancy index and, 90, 213–14
 treatments for, 7, 99–100
- menorrhagia
 contraceptives for management of, 7, 99–100
 in diabetic patients, 91, 215
 endometrial biopsy for, 74, 191–92, 267, 285
 hysterectomy for, 273–74, 295
 intrauterine system insertion and, 7, 99–100
 levonorgestrel contraceptive for, 264, 266–67, 281–82, 285
 management of, 269–70, 289
 polycystic ovarian syndrome with, 92, 216–17
- menstrual bleeding. *See* amenorrhoea; menorrhagia; oligomenorrhoea
- menstrual pain. *See* dysmenorrhoea
- menstrual suppression, 268, 287
- mestranol, 7, 99
- metformin, 226, 244
- methotrexate
 contraceptive use after, 34–35, 137
 ectopic pregnancy management, 35–36, 39, 138–39, 145
- metoclopramide, 271, 292
- mid-stream urine specimen, 224, 240
- mifepristone, 18, 115
- milk stasis, breastfeeding and, 58, 171

- Mirena® IUS
 complications with insertion, 15, 111
 for epileptic patients, 12, 107
 for menopausal symptoms and
 contraception, 90–91, 214
 for menorrhagia and contraception, 7,
 99–100
 for older women, 7, 12, 99–100, 106–7
- miscarriage
 advanced maternal age and, 32, 37,
 133, 141–42
 causes of recurrent, 38, 142
 copper coil IUD and, 262–63, 279
 ectopic pregnancy differential
 diagnosis and, 31, 132
 emergency management of, 35, 137–38
 expectant management of, 39, 144
 follow-up after, 38, 142–43
 incomplete, 39, 143–44
 missed, 33, 135
 partial hydatidiform mole, 30, 131
 placenta retention with, 74, 192
 psychological support for, 33, 37, 135,
 140–41
 recurrent, 32–33, 38, 133, 135, 142,
 274–75, 296
 rhesus isoimmunisation after, 33,
 134–35
 risk reduction interventions for
 recurrent, 33, 135
 sepsis after, 79–80, 200
 uterine artery embolization risk for,
 27, 127
- misoprostol, 18, 115
- missed miscarriage, management of, 33,
 135
- monochorionic twins, 55, 166, 232,
 251–52
- mosaic karyotype, 275–76, 298
- MSV manoeuvre, shoulder dystocia, 237,
 259
- Mullerian agenesis, 90, 213, 268–69,
 287–88
- Multiload Cu 375®, 10, 103–4
- multiparous pregnancies, 55, 166
- multiple births
 antenatal care and, 55, 166, 232,
 251–52
 labour and delivery, 55, 166
 maternal plasma DNA testing and, 44,
 149–50
- multiple sclerosis, 270, 289–90
- myomectomy, haemorrhage risk in,
 272–73, 293–94
- Nägele's rule, 31, 132
- natural conception, chances of, 28, 129
- nausea and vomiting, early pregnancy,
 30–34, 36, 40, 131–32, 134, 136–37,
 139, 145
- neonatal care
 ambiguous genitalia, 62, 176–77
 answers to single best answer
 questions, 171–90
 HIV infection prevention, 42, 59, 147,
 172–73
 infectious disease in, 60–61, 65,
 174–75, 181
 jaundice management, 232, 252
 maternal cocaine use and, 57, 170
 maternal diabetes and, 60, 174
 maternal obesity and risk assessment,
 59, 172
 single best answer questions, 58–72
 subgaleal haemorrhage, 66, 182
 syllabus, 58
 task prioritization for, 63, 74, 178, 192
- neonatal withdrawal syndrome, 49, 57,
 157, 170
- nifedipine, 39, 144
- night sweats, treatments for, 90–91, 214
- nipple soreness, breastfeeding and, 58,
 171, 238, 261
- non-English speaking patients, consent
 issues with, 230, 249, 270–71, 291
- non-hormonal contraceptives, 12, 107
- non-invasive prenatal testing (NIPT),
 233, 253–54
 maternal plasma DNA, 44, 54, 149–50,
 165, 224, 240–41
- nucleic acid amplification test (NAAT),
 80, 200
- NuvaRing®, 19, 116
- obesity
 birthing pool contraindicated with,
 234, 254–55
 dysmenorrhoea and, 87–89, 209, 211
 endometrial cancer and, 74, 91,
 191–92, 215, 267, 285
 'Enhanced Recovery Pathway,' 82–83,
 204
 hysterectomy complications with, 77,
 196
 labour and delivery management and,
 50, 67, 159–60, 183
 macrosomia risk and, 59, 172
 maternal plasma DNA testing
 inaccuracy and, 44, 149–50

- obesity (cont.)
 pregnancy and, 21, 44, 119–20, 149–51, 226, 231, 242–43, 251
 progesterone-only pill and, 276, 298
 thromboembolism risk and, 77, 196, 229, 247–48
 vaginal birth after caesarean and, 234, 254
 vitamin D deficiency and, 229, 247
- obstetric cholestasis. *See* intrahepatic cholestasis of pregnancy
- occipito-anterior fetal position, 235, 256
- occipito-posterior fetal position, 234, 254–55
- occupational health risks, pregnancy and, 44, 56–57, 150, 168–69, 223, 239–41
- older patients
 contraceptive counselling for, 6–7, 12, 14, 98–100, 106–7, 109
 dyspareunia in, 264–65, 282
 postmenopausal bleeding in, 74, 193
 post-operative wound dehiscence in, 88, 210–11
- oligomenorrhea, 19, 116
 polycystic ovarian syndrome, 84–85, 206
- oligospermia, 25, 124
- oophorectomy, 266, 284. *See also*
 salpingo-oophorectomy
 hysterectomy combined with, 77, 91, 196–97, 215, 267, 286
 ovarian cancer prevention and, 91, 215, 267, 286
- oral contraceptives. *See also* combined oral contraceptive; progesterone-only pill
 for adolescent patients, 5–6, 97
 age contraindications to, 14, 17, 109, 113
 antibiotic use and, 14, 110, 264, 281–82
 breakthrough bleeding and, 15, 110–11
 during early pregnancy, 13–14, 109
 estrogen compounds in, 7, 99
 health risks of, 9, 14, 17, 102–3, 109–10, 113
 high altitude trekking and, 275, 297–98
 orlistat and, 264, 281–82
 ovarian cancer protection and, 12–13, 82, 107–8, 203
 pelvic inflammatory disease risk and, 11, 106
 polycystic ovarian syndrome, 19, 116, 268, 286–87
 orlistat, 264, 281–82
 osteoporosis, 96, 222, 275–76, 298
- ovarian cancer
 BRCA1 gene and, 266, 284
 clomifene citrate risk for, 26, 126
 oophorectomy for prevention of, 91, 215, 267, 286
 oral contraceptives as protection from, 12–13, 82, 107–8, 203
 serum CA125 levels with, 81, 201–2, 270, 275, 290–91, 296–97
 tumour marker blood tests for, 80–81, 201
- ovarian cyst
 chocolate, 26, 126
 diagnosis and management of, 81, 93, 201–2, 217–18, 271, 291–92
 iliac fossa pain with, 275, 296–97
 pre-operative investigation, 77, 196–97
 risk of malignancy index and, 90, 213–14
 transverse lie of fetus due to, 70, 187
- ovarian cystectomy, during caesarean section, 70, 187
- ovarian failure, 93–94, 218
- ovarian hyperstimulation syndrome, 21–22, 29, 120, 130, 263, 279–80
- ovarian torsion, 22–23, 73–74, 80, 121, 191–92, 200
- ovulation
 investigations of, 23–24, 28–29, 122–23, 129–30
 obesity and, 21, 119–20
- ovulation induction, 26, 126. *See also* ovarian hyperstimulation syndrome
- oxybutynin, 271, 291
- oxytocin infusion
 cervical dilation and, 231, 250
 contraindications for, 235, 255–56
 postpartum haemorrhage management, 67, 183, 224–25, 241
- Paper 1, 223–61
 Paper 2, 278–301
 paracetamol, 57, 169
 paravaginal haematoma, 59, 172
 parity, 32, 133–34
 parvovirus B19, 56, 168, 227, 244
 Pearl index of contraceptive reliability, 7, 99
- pelvic floor reconstruction, latex allergy and, 275, 297

- pelvic inflammatory disease
 dye laparoscopy for diagnosis of, 20, 22, 118, 120–21
 oral contraceptives and risk of, 11, 106
 treatment of, 81, 202
 tubal patency, 21, 119
- pelvic pain
 dyschezia with, 89, 212
 endometriosis and, 89, 212, 263, 279
 laparoscopy for, 263, 279
 uterine fibroid with, 85–86, 207
- pelvic sepsis, in vitro fertilisation, 23, 122
- pelvic x-ray, 80, 200
- perineal tear
 infection, 67, 183
 postpartum management, 64, 178–79
 third degree, 56, 64, 168, 178–79, 227, 244–45
- periodontitis, risk for low birth weight and, 36, 139
- peripartum care
 answers to single best answer questions, 171–90
 breastfeeding complications, 58, 171
 single best answer questions, 58–72
 syllabus, 58
- peritonitis, after laparoscopic adhesiolysis, 25–26, 125
- Pfannenstiel incision, 21, 119
 bladder damage from, 6, 97–98
 postoperative ileus in elderly patients, 88, 210–11
- phenytoin, contraceptive use with, 12, 107
- phototherapy, 232, 252
- placenta. *See also* low lying placenta
 positioning of, 36–37, 46, 51, 140, 152–53, 160–61
 retention and delivery complications, 74, 192
- placenta abruptio
 abdominal pain and, 46, 51, 153, 161
 concealed abruptio, 51, 161
 haemorrhage and, 236, 257–58
 postpartum counselling concerning, 61, 175–76
 vaginal bleeding and, 42, 146–47
- placenta accreta, 36–37, 140, 237, 260
- placenta praevia
 antenatal screening for, 46, 153
 vaginal bleeding and, 42, 146–47, 227, 245
- placental insufficiency, 44, 150–51, 231, 251
- placental perfusion, 236–37, 258–59
- polycystic ovarian syndrome (PCOS)
 amenorrhoea with, 90, 213
 contraceptive counselling with, 18–19, 115–16, 268, 286–87
 endometrial cancer and, 276–77, 299–300
 endometrial hyperplasia, 79, 199
 facial hirsutism and, 19, 116, 268, 286–87
 in vitro fertilisation complications and, 21–22, 29, 120, 130
 menorrhagia and, 92, 216–17
 progesterone therapy for, 84–85, 206
- polyhydramnios, 43–44, 149
- polymorphic eruption of pregnancy, 41–42, 146
- polyp, cervical, 92, 216
- postcoital bleeding
 cervical lesions, 75, 193–94
Chlamydia trachomatis, 93, 217, 264, 280–81
 in pregnancy, 46, 153
- postmenopausal bleeding
 anticoagulants in, 74, 193
 endometrial cancer and, 82, 203
 endometrial hyperplasia and, 79, 199
 hysterectomy for, 76, 194–95
- postmenopausal patients
 bone-sparing drug treatment in, 96, 222
 prolapse in, 265, 282
- postoperative ileus, in elderly patients, 88, 210–11
- postpartum care
 cholestasis, 66, 181–82
 contraceptive counselling, 12, 17, 107, 113
 depression management, 53–55, 62, 163, 165–66, 177
 diabetes management, 62, 176
 direct maternal death during, 64, 179
 episiotomy, 67, 183
 for headache, 61, 174–75
 hypertension management, 71, 189
 lactation suppression, 71, 188
 lochia, 66, 182–83
 management of complications, 78, 198
 perineal tear, 64, 178–79
 pregnancy counselling during, 61, 175–76
- pulmonary embolus, 60, 173–74
- sepsis, 63, 79–80, 178, 200
- sterilisation counselling, 16, 112
- task prioritization in, 63, 74, 178, 192

- postpartum care (cont.)
 - third degree tears, 56, 168, 227, 244–45
 - urine retention, 65–66, 181
 - vaginal bleeding, 65, 70, 78, 180–81, 187, 198
 - venous thromboembolism, 61–62, 64, 176, 179
 - wound dehiscence, 65, 180
- postpartum counselling
 - next pregnancy, 71–72, 184–89
 - placenta abruptio, 61, 175–76
 - vaginal birth after caesarean, 67–68, 184
- postpartum haemorrhage (PPH)
 - assisted vaginal delivery and risk of, 237, 259
 - ‘grand multip’ pregnancies, 45, 50, 152, 159–60, 237, 260
 - Jehovah’s Witness patients, 63–64, 178
 - management of, 67–68, 183–84, 224–25, 241
 - placenta retention and delivery complications, 74, 192
 - pre-eclampsia and, 224–25, 235, 241, 256
 - prioritization for patients with, 74, 192
 - pulmonary oedema with, 273, 294
 - red cell antibodies and, 51, 160
 - research project participation and, 69, 185–86
- postpartum psychosis, 53, 59–60, 63, 163, 173, 177–78
- Power of Attorney, consent issues and, 78, 197–98
- pre-conceptual counselling, bipolar disorder, 49, 157–58
- pre-eclampsia
 - aspirin for prevention of, 56, 167–68, 232–33, 252–53
 - direct maternal death with, 64, 179
 - headache during pregnancy and, 43, 45, 47, 148, 151–52, 155
 - postpartum haemorrhage with, 224–25, 235, 241, 256
- pregnancy. *See also* early pregnancy;
 - termination of pregnancy
 - abdominal pain in, 31, 38, 45–46, 50–51, 65, 132, 143, 151–53, 158–59, 161, 181
 - in adolescent patients, 46–47, 153–54
 - amenorrhoea in, 93–94, 218
 - answers to single best answer questions, 146–70
 - antidepressant medications in, 49, 157
 - appendicitis in, 45–46, 152
 - cardiac arrest in, 59, 171
 - cardiac contraindications for, 7–8, 100–1
 - chances of conceiving, 28, 129
 - chest pain in, 52, 162
 - chickenpox and, 44, 56–57, 150, 168–69, 223, 225, 228, 239–42, 246
 - combined oral contraceptive use
 - during early, 13–14, 109
 - dental care during, 36, 139
 - depression and, 44–45, 49, 151, 157, 230, 249
 - diabetes in, 43–44, 149
 - domestic violence and, 48, 156, 235, 256–57
 - drugs contraindicated in, 39, 49, 144, 157
 - in epileptic patients, 55, 167
 - foods to avoid in, 37, 141
 - ‘grand multip,’ 45, 50, 152, 159–60
 - headache during, 47, 155
 - headache in, 43, 45, 148, 151–52
 - herpes simplex virus infection in, 43, 148–49
 - heterotopic, 34, 136
 - HIV infection in, 42, 59, 147, 172–73, 227–28, 245–46
 - with HIV-positive male partners, 22, 121
 - hypertension in, 39, 44, 50, 56, 144, 150–51, 159, 167–68, 223, 231, 239–40, 251
 - infectious disease in, 44–47, 52, 56–57, 150–51, 153–54, 161–62, 168–69, 223, 225, 227–28, 230–31, 233, 239–42, 244, 246, 250, 253
 - inter-pregnancy interval, 71–72, 184–89
 - with intrauterine contraceptive system, 6, 31, 98, 132
 - length of normal, 31, 132
 - limb swelling in, 50–51, 160
 - measles and, 227, 244
 - after methotrexate treatment, 34–35, 137
 - monochorionic twins in, 55, 166
 - obesity in, 21, 44, 119–20, 149–51, 226, 231, 242–43, 251
 - psychiatric problems in, 49, 53–55, 59–60, 63, 157–58, 163, 165–66, 173, 177–78, 230, 249
 - pubic symphysis pain in, 43, 57, 148, 169

- respiratory rate and, 232, 251
 retroverted uterus complications in,
 31–32, 133
 rhesus complications, 33, 52, 54,
 134–35, 162–63, 165
 single best answer questions, 41–57
 skin conditions in, 41–42, 146
 smoking and, 52, 71–72, 162, 184–89
 surrogate, 28, 128
 syllabus, 41
 travel during, 48, 53, 156, 163–64, 238,
 260
 ultrasound scan of, 266, 284–85
 of unknown location, 37–38, 140–41,
 143
 vaccination and, 55, 167, 226, 233, 243,
 253
 vaginal bleeding in late, 42, 46–47, 53,
 146–47, 153–54, 163–64
 pre-implantation genetic diagnosis
 (PGD), 25, 124
 pre-labour premature rupture of
 membranes (PPROM), 71–72,
 184–89, 225, 242
 premature ovarian insufficiency (POI),
 276, 299
 premature rupture of membranes, 42,
 147
 prematurity, ovarian hyperstimulation
 syndrome risk for, 29, 130
 premenstrual syndrome (PMS), initial
 management of, 94–95, 220
 pre-natal screening and diagnosis, 54,
 164–65
 non-invasive prenatal testing, 44, 54,
 149–50, 165, 224, 233, 240–41,
 253–54
 pre-operative investigations
 dye laparoscopy, 21, 23, 119, 121–22
 gynaecological surgery, 77, 88–89,
 196–97, 211–12
 thromboprophylaxis risk, 89, 211–12
 progesterone, measurement of, 23–24,
 28–29, 122–23, 129–30
 progesterone therapy, for polycystic
 ovarian syndrome, 84–85, 206
 progesterone-only pill (POP), 8, 17, 101,
 113
 for adolescent patients, 5–6, 97
 obesity and, 276, 298
 progestogen injection. *See* Depot
 medroxyprogesterone acetate
 progestogens, health risks of, 14, 109–10
 promethazine, 34, 136–37
 proteinuria
 abdominal pain in pregnancy and, 45,
 151–52
 headache during pregnancy and, 47,
 155
 psychiatric problems in pregnancy
 bipolar disorder, 49, 157–58, 230, 249
 depression, 44–45, 49, 151, 157, 230,
 249
 postpartum psychosis, 63, 177–78
 psychosis, 53, 59–60, 163, 173
 in sexually abused patients, 8, 101
 suicide, 54–55, 165–66, 230, 249
 psychological support, for miscarriage,
 33, 37, 135, 140–41
 psychosis, 53, 59–60, 63, 163, 173, 177–78
 pubarche, 93, 218
 puberty, normal development during,
 93, 218
 pubic symphysis pain, 43, 57, 148, 169
 puerperal sterilisation, 16, 112
 puerperium
 antidepressant medications in, 49, 157
 diabetes management in, 62, 176
 psychosis risk factors, 63, 177–78
 pulmonary embolus
 anticoagulant therapy for, 60, 173–74
 hormone replacement therapy and,
 277, 300–1
 obesity and risk of, 77, 196
 pulmonary oedema, 273, 294
 QT interval prolongation, 13, 108
 quick starting, contraception, 13–14, 109
 radiotherapy, haematometria following,
 86, 208
 rape victims, emergency contraception
 for, 14–15, 110
 rash, polymorphic eruption of
 pregnancy, 41–42, 146
 recurrent miscarriage, 32, 133, 274–75,
 296
 causes of, 38, 142
 risk reduction interventions for, 33,
 135
 red cell antibodies, postpartum
 haemorrhage and, 51, 160
 red degeneration of fibroid, 50, 158–59
 renal ultrasound, for unilateral absence
 of vas deferens, 19, 116
 respiratory distress, neonatal, 60–61, 174
 respiratory rate, pregnancy and, 232, 251
 retroversion, uterus, 31–32, 133

- rhesus isoimmunisation, 33, 46, 52, 54,
 134–35, 153, 162–63, 165, 231, 236,
 250–51, 258
- ricketts, 229, 247
- rising spinal block, 67, 183
- Risk of Malignancy Index (RMI), 90, 93,
 213–14, 217–18, 275, 296–97
- Rokintansky syndrome, 90, 213
- rubella, pregnancy and exposure to, 227,
 230–31, 244, 250
- rubella antibody level blood test, 23, 122
- rupture. *See* uterine rupture
- salmonella poisoning, 37, 141
- salpingectomy, ectopic pregnancy and,
 35–36, 138–39
- salpingo-oophorectomy
 complications, 75–76, 78, 194, 197
 ‘Enhanced Recovery Pathway,’ 82–83,
 204
 ovarian cancer and, 266, 284
 ovarian cyst assessment, 77, 196–97
 ureteric injury, 80, 201
- semen analysis, 24, 26–28, 123–24,
 126–27, 129
- sepsis
 lactate levels in, 38, 142
 pelvic, in vitro fertilisation and, 23, 122
 postpartum, 63, 79–80, 178, 200
- sepsis six bundle, 38, 142
- sex chromosome disorders, infertility
 with, 24–25, 124
- sexual abuse
 dyspareunia with, 8, 101
 pregnancy in adolescent patients and,
 46–47, 153–54
- sexual ambiguity, neonatal, 62, 176–77
- sexual health assessment
 answers to single best answer
 questions, 97–117
 single best answer questions, 5–19
 syllabus, 5
- sexual intercourse
 chances of conception with, 28, 129
 low lying placenta and avoidance of,
 46, 152–53
- sexually transmitted infection (STI), 276,
 298–99. *See also specific infections*
 in adolescent patients, 46–47, 153–54
- Sheehan syndrome, 90, 213
- shingles, exposure during pregnancy,
 56–57, 168–69
- shoulder dystocia, 237, 259
- shoulder tip pain, ectopic pregnancy, 31,
 132
- sickle cell disease, 80, 200
- skin conditions in pregnancy, 41–42, 146
- ‘slapped cheek syndrome,’ 56, 168
- smoking, pregnancy and, 52, 71–72, 162,
 184–89
- sodium valproate, 55, 167
- sperm concentration, 26–27, 126–27
- sperm count, 24, 123–24
- spinal block, 67, 183
- sterilisation
 complications following, 6, 97–98
 counselling concerning, 7, 16, 99, 112
 ectopic pregnancy risk with, 7, 99
 laparoscopic techniques, 6, 97–98, 264,
 273, 281, 294
 reversal of, 7, 99, 264, 281
- stillbirth, 238, 260–61
 registration of, 65, 180
 suppression of lactation after, 71, 188
- strawberry cervix, 17–18, 114
- Streptococcus* A infection, 79–80, 200
- Streptococcus* B infection. *See* group
 B streptococcus
- stress incontinence
 bladder pressure study for, 265, 283
 treatment for, 273, 294–95
- subfertility. *See* infertility
- subgaleal haemorrhage, 66, 182
- sudden infant death, 238, 260–61
- suicide, 54–55, 165–66, 230, 249
- sulfasalazine, 25, 124
- suppression of lactation, 71, 188
- surgical evacuation, miscarriage
 management, 35, 39, 137–38, 143–44
- surrogate pregnancy, success of, 28, 128
- suxamethonium apnoea, 88, 211
- tardive dyskinesia, 271, 292
- teenagers. *See* adolescent patients
- termination of pregnancy
 consent in adolescent patients for,
 77–78, 197
 early medical abortion, 18, 115
 maternal risk as indication for, 7–8,
 100–1
 performance in UK of, 7–8, 10–11,
 15–16, 100–1, 104–5, 111–12
 ultrasound scan with, 18, 114–15
- testicular feminization, 268–69, 287–88
- testosterone replacement therapy, 91, 215
- thelarche, 93, 218

- thiamine, 32, 134
- third degree tears
 forceps delivery and, 64, 178–79
 management of, 56, 168, 227, 244–45
- thromboembolism risk. *See also*
 pulmonary embolus; venous thromboembolism
 anticoagulant therapy for, 60–62, 173–74, 176
 combined oral contraceptive use, 14, 17, 109–10, 113
 forceps delivery, 64, 179
 gynaecological surgery and, 89, 211–12
 hyperemesis and, 40, 145
 obesity and, 77, 196, 229, 247–48
 red flag symptoms, 61, 174–75
 travel during pregnancy and, 48, 156
- thrush infection
 therapy for, 9–10, 13, 103, 108
 vaginal discharge with, 18, 115, 270, 290
- thyroid patients
 antenatal management of, 57, 169–70
 lichen sclerosus in, 94, 219–20
- thyroxine, 57, 169–70
- toxoplasmosis, 37, 141
- tranexamic acid, 224–25, 241
- transfusion
 haemorrhage management and, 51, 68, 160, 184
 Jehovah's Witness patient care and, 39, 63–64, 77, 144, 178, 196
 twin-twin transfusion syndrome, 232, 251–52
- transgender (trans) men, cervical screening for, 13, 108
- transient ischaemic attack (TIA), 9, 102–3
- trans-vaginal ultrasound
 CA125 levels and, 81, 201–2
 dysmenorrhoea diagnosis, 87–89, 209, 211
 ectopic pregnancy diagnosis, 38, 143
- transverse lie of fetus, 42, 147
 causes of, 70, 187
- travel
 contraceptive counselling for, 11–12, 106
 during pregnancy, 48, 53, 156, 163–64, 238, 260
Trichomonas vaginalis, 17–18, 114, 270, 290
- trisomies
 chorionic villus sampling for, 232, 252
 maternal plasma DNA testing for, 44, 149–50, 224, 240–41
- tubal patency
 ectopic pregnancy and, 7, 99
 pelvic inflammatory disease, 21, 119
 reversal of sterilisation and, 264, 281
- tumour marker blood tests, 80–81, 201.
See also CA125 blood test
- Turner syndrome, 86–87, 92–93, 209, 217, 262, 275–76, 278–79, 298
- twin births
 antenatal care and assessment of, 232, 251–52
 labour and delivery planning for, 55, 166
 maternal plasma DNA testing and, 44, 149–50
- twin-twin transfusion syndrome, 232, 251–52
- UK Medical Eligibility Criteria for contraceptive use (UKMEC), 9, 102–3
- ulcerative colitis, 25, 124
- ulipristal acetate (EllaOne®), 10, 14–15, 104, 110, 263–64, 280
- ultrasound guided drainage, 236, 257
- ultrasound scan
 CA125 levels and, 81, 201–2
 chocolate ovarian cysts on, 26, 126
 dysmenorrhoea diagnosis, 87–89, 209, 211
 early pregnancy, 266, 284–85
 ectopic pregnancy diagnosis, 38, 143
 growth, 46–47, 153–54
 intrauterine system location, 15, 111
 ovarian cyst diagnosis, 93, 217–18
 risk of malignancy index and, 90, 213–14
 snowstorm appearance on, 36, 139, 268, 287
 termination of pregnancy and, 18, 114–15
 for unilateral absence of vas deferens, 19, 116
- unexplained infertility, 25–26, 124–26
- United Kingdom
 maternal morbidity and mortality in, 52–53, 163
 termination of pregnancy procedures in, 7–8, 10–11, 15–16, 100–1, 104–5, 111–12

- United States, maternal morbidity and mortality in, 52–53, 163
- urea assessment, 75–76, 194
- ureteric injury, hysterectomy risk of, 80, 87–88, 201, 210
- urethral diverticulum, 86, 207–8
- urinary disorders
- bladder pain syndrome, 96, 222
 - catheterisation for urine retention, 65–66, 181, 230, 248–49
 - cystoscopy for diagnosis of, 85, 207, 269, 288
 - herpes genitalis, 17, 113
 - paravaginal haematoma with, 59, 172
 - in postpartum period, 65–66, 181
 - retroverted uterus complications in pregnancy, 31–32, 133
 - urethral diverticulum, 86, 207–8
 - urgency and incontinence, 92, 215–16, 265, 273, 283, 294–95
- urinary hCG, 75, 194
- urinary tract infection, 76, 90, 195, 213, 224, 240
- uterine anomalies, retroverted uterus, 31–32, 133
- uterine artery embolization, miscarriage rate after, 27, 127
- uterine fibroids
- cervical smears and appearance of, 265, 282–83
 - contraceptive options with, 11, 106
 - miscarriage rate after uterine artery embolization for, 27, 127
 - painful, 85–86, 207
 - red degeneration of, 50, 158–59
- uterine prolapse, 89–90, 212–13, 265, 282
- uterine rupture
- home delivery and risk of, 51, 161
 - vaginal birth after caesarean and, 234, 254
- uterotonics, 224–25, 241
- uterus, evacuation of, 35, 39, 78, 137–38, 143–44, 198
- vaccination
- human papilloma virus, 16–17, 113–14, 263, 265–66, 280, 283–84
 - influenza, 55, 167, 233, 253
 - pregnancy and, 55, 167, 226, 233, 243, 253
 - rubella, 23, 122
 - yellow fever, 226, 243
- vaginal birth after caesarean (VBAC)
- chance of successful, 49–50, 158
 - postpartum counselling concerning, 67–68, 184
 - risk factors for, 228, 246
 - uterine rupture and, 234, 254
- vaginal bleeding
- in early pregnancy, 30, 38, 131, 143
 - endometrial cancer and, 82, 203
 - granulation tissue, 78, 197
 - large loop excision of the transformation zone, 75, 193
 - in late pregnancy, 42, 46–47, 53, 146–47, 153–54, 163–64
 - placenta abruptio, 42, 146–47
 - placenta praevia and, 42, 146–47, 227, 245
 - placental delivery complications, 74, 192
 - in postpartum period, 65, 70, 78, 180–81, 187, 198
 - Rhesus negative patients, 231, 250–51
- vaginal delivery
- assisted, 48, 69, 156–57, 185, 237, 259
 - postpartum complications, 64–65, 70, 78, 178–81, 187, 198
- vaginal discharge
- bacterial vaginosis and, 270, 290
 - infectious disease in pregnancy and, 45, 151
 - pre-labour premature rupture of membranes and, 225, 242
 - Trichomonas vaginalis*, 17–18, 114, 270, 290
 - vulvovaginal candidiasis, 18, 115, 270, 290
- vaginal hysterectomy, 89–90, 212–13
- vaginal prolapse, 89–90, 212–13, 265, 282
- vaginal swelling, urethral diverticulum, 86, 207–8
- vaginitis, 17–18, 114
- atrophic, 94, 219
- valproate, 55, 167
- Valsalva manoeuvre, contraindications to, 69, 185
- varicella zoster immune globulin (VZIG), 223, 225, 228, 239–42, 246
- vas deferens, unilateral absence of, 19, 116
- venous thromboembolism (VTE)
- combined oral contraceptive risk of, 14, 17, 109–10, 113
 - forceps delivery and risk of, 64, 179

- gynaecological surgery and, 89, 211–12
- high altitude trekking and, 275, 297–98
- hormone replacement therapy and, 277, 300–1
- in post-caesarean patients, 61–62, 176
- travel during pregnancy and, 48, 156
- ventouse delivery, subgaleal haemorrhage after, 66, 182
- verbal consent, 69, 78, 186, 197–98
- virgo intacta, contraceptive counselling for, 19, 116
- vitamin A, 37, 141
- vitamin B1, 32, 134
- vitamin D deficiency, 229, 247
- vomiting. *See also* hyperemesis; nausea and vomiting
 - appendicitis, 45–46, 152
 - ovarian torsion, 22–23, 121
- vulval inflammation, 17–18, 114
 - candidiasis, 18, 115
 - contact dermatitis, 94, 218–19
 - herpes genitalis, 17, 113
 - lichen planus, 95, 221
 - lichen sclerosus, 87, 94, 209–10, 219–20, 272, 292–93
 - lichen sclerosus et atrophicus, 82, 203–4
- vulvovaginal candidiasis
 - therapy for, 9–10, 13, 103, 108
 - vaginal discharge with, 18, 115, 270, 290
- vulvo-vaginal swab, 80, 200
- warfarin, postmenopausal bleeding and, 74, 193
- warts. *See* genital warts
- water birth, 234, 254
- weight loss, for morbid obesity, 21, 119–20
- Wernicke’s encephalopathy, 32, 134
- whooping cough, vaccination, 55, 167
- withdrawal syndrome, neonatal, 49, 57, 157, 170
- World Health Organisation, 52–53, 163, 274, 295
- wound dehiscence, 65, 180
 - risk factors for, 88, 210–11
- wound infection
 - caesarean section, 234, 255
 - episiotomy, 67, 183
- written consent, 69, 78, 186, 197–98
- Xonvea, 34, 136–37
- x-ray
 - intrauterine system location, 15, 111
 - pelvic, 80, 200
- yellow fever vaccine, 226, 243